DRGs in Transfusion Medicine and Hemotherapy in Germany

Area of Science:

• Health Services Research
• Medical Economics
• Transfusion Medicine

Background:

• Inpatient transfusion medicine and hemotherapy are integrated into the German Diagnosis Related Groups (G-DRG) system.
• Existing G-DRG reimbursement may not adequately cover the costs for many patients requiring these treatments.
• There is a need for improved definitions and pricing within the G-DRG system for transfusion medicine.

Purpose of the Study:

• To analyze the current reimbursement landscape for transfusion medicine and hemotherapy in Germany.
• To identify challenges and propose solutions for cost-covering reimbursement.
• To emphasize the importance of health service research in this domain.

Main Methods:

• Analysis of the German Diagnosis Related Groups (G-DRG) system.
• Review of existing remuneration mechanisms, including Patient Clinical Complexity Level (PCCL), DRG splits, additional remuneration fees (Zusatzentgelte, ZE), and the New Diagnostic and Treatment Methods (NUB) system.
• Discussion of the impact of these systems on the adoption of innovative treatments.

Main Results:

• Specific DRGs exist for transfusion medicine, but reimbursement may be insufficient.
• Multiple systems (PCCL, DRG splits, ZE) aim to increase remuneration for complex cases or high-cost products.
• The NUB system facilitates reimbursement for innovative treatments not covered by DRGs.

Conclusions:

• Intensified health service research is essential to define adequate DRG prices for transfusion medicine and hemotherapy.
• Effective use of supplementary remuneration systems (ZE, NUB) is crucial for incorporating medical progress and innovative therapies.
• Ensuring cost-covering reimbursement is vital to prevent financial barriers to accessing advanced medical treatments.